Contraceptive Efficacy Study of Ovaprene

Contraception Clinical Trial

Official title:

A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06127199
• Other study ID #: DR-OVP-002
• Status: Recruiting
• Phase: N/A
• Start date: December 19, 2023
• Est. completion date: September 2025

Study information

• Verified date: April 2024
• Source: Daré Bioscience, Inc.
• Contact: Christine Mauck, MD
• Phone: www.ovaprenestudy.com
• Email: cmauck[@]darebioscience.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 656
• Est. completion date: September 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Sexually active people assigned female at birth, at risk for pregnancy and desiring contraception.
• General good health, by subject history and per investigator judgement
• Age 18 through 40 years, inclusive; approximately 66 subjects >35 years old at visit 2 will be the Enrolled-Eligible Population
• In a relationship with a person assigned male at birth who meets eligibility criteria below. --At least 18 years old, not known to be subfertile or infertile
• Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days, without heave bleeding that lasts longer than 5 days
• Be willing to stop their current method of contraception (with the exception of condoms) before Visit 2. Participants must experience at least one subsequent menstrual bleed before inserting Ovaprene. Participants using injectable contraception must be at least 9 months post their last dose at screening and have experienced at least 2 subsequent regular menstrual bleeds that were part of cycles of 21-35 days. After stopping their current method of contraception, subjects must either abstain fro vaginal sex or use condoms before inserting their first Ovaprene
• Not be actively desiring pregnancy for at least 13 months and be willing to accept an unknown risk of pregnancy
• Expect to engage in at least 4 acts of heterosexual vaginal intercourse per cycle during the study.
• Be willing to only use Ovaprene as the sole method of contraception over the course of the study
• Agree not to participate in any other clinical trials during the course of the study
• Be willing and able to comply with study procedures and to return to the clinic for scheduled follow-up visits
• Microbiota/innate immunity and colposcopy subsets only:
• Be willing to avoid vaginal sex and using tampons and other intravaginal products for 48 hours prior to clinic visits; and be willing to comply with subset procedures

Exclusion Criteria:

• Currently pregnant and/or have a positive urine pregnancy test at screening.
• Have an allergy to the ingredients in Ovaprene
• Have a history of toxic shock syndrome
• Have a history of hereditary hemochromatosis
• Be breastfeeding an infant
• Have a history suggestive of infertility, defined as any of the following: known history of ectopic pregnancy or other fertility problem; sterilization/permanent contraception; endometriosis or hospitalization for pelvic inflammatory disease (PID) unless subject has had a subsequent spontaneous intrauterine pregnancy; or use of medications that could cause subfertility such as gonadotropin-releasing hormone agonists
• Currently have postcoital bleeding
• Have contraindications to pregnancy (medical condition) or chronic use of medications contraindicated in pregnancy
• Have a history of clinically significant uterine prolapse, cystocele, or rectocele that has required surgical intervention or pessary use
• Positive human immunodeficiency virus (HIV) test at screening
• Have exclusionary results on human papilloma virus (HPV) screening/cytology (subjects>/=21 years old) at screening or require treatment or follow-up for an abnormal Pap smear or HPV test that would be needed during the study.
• Have had a vaginal or cervical biopsy within 1 month or vaginal surgery within the 3 months prior to screening
• Known current drug or alcohol abuse which, in the opinion of the investigator, could impact study compliance
• Have previously been included in the Enrolled-Eligible Population
• Is a direct employee or immediate family member of the Sponsor company, site Investigators or study staff
• Have taken any investigational drug or used any investigational device within the 30 days prior to screening
• Have a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results
• Microbiota/innate immunity subset only:

--systemic use in the last 2 weeks prior to screening or anticipated use during the study of antibiotics (other than those used to treat urinary tract infection (UTI), candidiasis, or bacterial vaginosis(BV) diagnosed at Visit 1) or antivirals;

• If male partner has or is suspected to have had an HIV infection or other sexually transmitted infection
• if male partner has a known sensitivity or allergy to the ingredients in Ovaprene
• If male partner has previously participated in this study or has taken any investigational drug or used any investigational device within 30 days prior to the female subject's screening
• If the male partner has a history of any severe acute or chronic medical or psychiatric condition that could increase the risk associated with trial participation or could interfere with the interpretation of trial results.

Related Conditions & MeSH terms

• Contraception

Intervention

Device:
• Ovaprene
Non-hormonal intravaginal ring

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	University of Colorado Denver	Aurora	Colorado
United States	The Johns Hopkins University	Baltimore	Maryland
United States	Essential Health Access (Berkeley)	Berkeley	California
United States	Boston Medical Center	Boston	Massachusetts
United States	Einstein College of Medicine	Bronx	New York
United States	University of Cincinnati	Cincinnati	Ohio
United States	Case Western	Cleveland	Ohio
United States	University of Hawaii	Honolulu	Hawaii
United States	Essential Access Health	Los Angeles	California
United States	Columbia University	New York	New York
United States	Rutgers Medical Center	Newark	New Jersey
United States	Eastern Virginia Medical School	Norfolk	Virginia
United States	University of Pennsylvania Penn Obstetric Gynecology Associates	Philadelphia	Pennsylvania
United States	Magee-Women's Hospital	Pittsburgh	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	University of California at Davis	Sacramento	California
United States	Washington University	Saint Louis	Missouri
United States	University of Utah	Salt Lake City	Utah
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Daré Bioscience, Inc.	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of pregnancy rate	Measurement of number of pregnancies over 13 menstrual cycles (13-cycle Pearl Index)	12 months